Remote and In-Person Testing for Autonomic Dysfunction in Adult Survivors of Leukemia and Lymphoma

What this Trial Is About

This research aims to evaluate remote methods for diagnosing cardiac autonomic dysfunction AD in survivors of childhood cancers, specifically acute lymphoblastic leukemia ALL and Hodgkins lymphoma HL. The study compares remote heart rate variability HRV measurement using a wrist biosensor against the traditional in-person Ewing battery test. Identifying AD earlier through remote testing could enable quicker diagnosis and reduce health risks for these survivors. Participants undergo an in-person Ewing battery assessment lasting 60 to 90 minutes, which includes tests of heart rate and blood pressure changes during specific activities. They also complete the Composite Autonomic Symptom Scale 31 COMPASS31 questionnaire about symptoms of AD. After the in-person visit, participants wear a wrist biosensor heart monitor for 7 days at home to measure heart rate variability remotely. Throughout the study, participants complete symptom questionnaires either before or after the in-person assessment. Researchers measure heart rate variability over 7 days post-visit, scores from the COMPASS31 questionnaire, and results from the Ewing battery performed during the on-campus visit. The study monitors participants for up to 7 days after the clinical exam to compare the accuracy of remote and in-person testing methods.

Assessment of Remote Approaches for Identification of Autonomic Dysfunction Among Survivors of Leukemia and Lymphoma